Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

James D. Griffin, MD


Medical Oncology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Leukemias
  • Myelodysplasia

Contact Information

  • Office Phone Number617-632-3360
  • Fax617-632-2260

Bio

Dr. Griffin received his MD from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at DFCI. In 1981, he joined the staff of DFCI, where he is now director of the Leukemia Program and chair of the Department of Medical Oncology. He also serves on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center.

Board Certification:

  • Hematology, 1978
  • Internal Medicine, 1977
  • Medical Oncology, 1981

Fellowship:

  • Dana-Farber Cancer Institute, Oncology
  • Dana-Farber Cancer Institute, Tumor Virology
  • Massachusetts General Hospital, Hematology & Oncology

Residency:

  • Johns Hopkins Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Recent Awards:

  • Dr. Anthony Cortese Award 2001
  • Johns Hopkins University Society of Scholars 2003

Research

Mechanisms of Transformation in Leukemia

There are several major projects in our laboratory. The first involves trying to understand how tyrosine kinase oncogenes cause certain types of chronic leukemia. The prototypic tyrosine kinase oncogene, BCR-ABL, causes human chronic myeloid leukemia and rapidly transforms hematopoietic cells in mice. BCR-ABL encodes an activated tyrosine kinase that is localized to the cytoplasm and cytoskeleton. In addition, mutations of the tyrosine kinase oncogene FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lvmphocytic leukemia or myelodysplastic syndrome. Recently, mutations in the JAK2 tyrosine kinase oncogene have been shown to cause polycythemia vera and some other myeloproliferative diseases.Each of these mutations results in constitutive activation of the kinase and unregulated signals causing growth, blocking differentiation, and enhancing viability. We are interested in defining the signaling pathways leading to these biological effects, since many of these pathways constitute potential targets for drug development. Over the last few years, we have participated in the development of novel small-molecule inhibitors for BCR-ABL (AMN107) and FLT3 (PKC412), both of which are currently in clinical trials; we are also working actively to develop inhibitors of JAK2.The second major project is in signal transduction of Notch receptors. Notch is a highly conserved signaling pathway that regulates development of many tissues, and in hematopoiesis Notch is likely to play a role in the differentiation of T cells and B cells. We have cloned new components in the Notch signaling pathway, and a number of studies are ongoing with regard to these new nuclear proteins. One member of this family of proteins, called MAML2, has now been shown to be involved in a recurrent chromosomal translocation, t(11;19), in most cases of mucoepidermoid cancer, and appears to cause that disease.Our laboratory also is involved in projects related to the development of novel therapies for hematologic malignancies, involving immunotherapy, gene therapy, and chemotherapy.

The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. JCI Insight. 2021 Apr 08; 6(7).
View in: PubMed

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020 Dec 22; 13(1).
View in: PubMed

Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 Sep; 34(9):2543.
View in: PubMed

Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. 2020 Aug 10; 37(9):167.
View in: PubMed

Current therapies under investigation for COVID-19: potential COVID-19 treatments. Can J Physiol Pharmacol. 2020 Aug; 98(8):483-489.
View in: PubMed

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324.
View in: PubMed

Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020 04; 122(8):1175-1184.
View in: PubMed

Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. J Cell Mol Med. 2020 03; 24(5):2968-2980.
View in: PubMed

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 2020 02; 24(3):2145-2156.
View in: PubMed

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia. 2020 02; 34(2):625-629.
View in: PubMed

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. Br J Haematol. 2019 11; 187(4):488-501.
View in: PubMed

Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2019 Jul; 121(3):282.
View in: PubMed

Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study. Eur J Haematol. 2019 Apr; 102(4):341-350.
View in: PubMed

Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk Res. 2018 09; 72:34-44.
View in: PubMed

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. Onco Targets Ther. 2018; 11:175-182.
View in: PubMed

Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological MalignanciesPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry. 2018 02 06; 57(5):477-478.
View in: PubMed

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chem Biol. 2018 01 18; 25(1):88-99.e6.
View in: PubMed

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 2017 Dec 15; 8(66):109973-109984.
View in: PubMed

Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
View in: PubMed

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044.
View in: PubMed

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06.
View in: PubMed

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget. 2017 Sep 15; 8(40):67639-67650.
View in: PubMed

Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem. 2017 02 01; 25(3):838-846.
View in: PubMed

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem. 2017 02 15; 25(4):1320-1328.
View in: PubMed

Simultaneous inhibition of Vps34 kinase would enhance PI3Kd inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. 2016 Aug 16; 7(33):53515-53525.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

Characterization of selective and potent PI3Kd inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. 2016 May 31; 7(22):32641-51.
View in: PubMed

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget. 2016 May 17; 7(20):29131-42.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett. 2016 May 12; 7(5):476-81.
View in: PubMed

Gene expression profiling analysis of CRTC1-MAML2 fusion oncogene-induced transcriptional program in human mucoepidermoid carcinoma cells. BMC Cancer. 2015 Oct 26; 15:803.
View in: PubMed

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leuk Res. 2015 Sep 09.
View in: PubMed

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. . 2015 Oct; 14(10):2249-59.
View in: PubMed

Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015 May 14; 125(20):3133-43.
View in: PubMed

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia. 2015 Jul; 29(7):1555-1563.
View in: PubMed

Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. Arch Toxicol. 2014 Dec; 88(12):2233-42.
View in: PubMed

Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res. 2014 Nov 01; 20(21):5483-95.
View in: PubMed

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 2015 Jan; 29(1):27-37.
View in: PubMed

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol. 2014 May 16; 9(5):1086-91.
View in: PubMed

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 May 01; 123(18):2816-25.
View in: PubMed

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014 Mar 01; 20(5):1135-45.
View in: PubMed

Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol. 2013 Oct; 20(10):1221-3.
View in: PubMed

Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Curr Cancer Drug Targets. 2013 Sep; 13(7):735-48.
View in: PubMed

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013 Oct 18; 8(10):2145-50.
View in: PubMed

Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol. 2013 Jul 19; 8(7):1423-8.
View in: PubMed

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis. Curr Med Res Opin. 2013 Jun; 29(6):623-31.
View in: PubMed

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One. 2013; 8(2):e56473.
View in: PubMed

The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11.
View in: PubMed

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin. 2012 Jul; 28(7):1155-62.
View in: PubMed

Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. Bioorg Med Chem Lett. 2012 Aug 15; 22(16):5297-302.
View in: PubMed

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRa and kit. Bioorg Med Chem Lett. 2012 Jul 15; 22(14):4579-84.
View in: PubMed

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 2012 Oct; 26(10):2233-44.
View in: PubMed

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012 May; 26(5):985-90.
View in: PubMed

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011; 6(9):e25351.
View in: PubMed

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia. 2012 Apr; 26(4):708-15.
View in: PubMed

The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2012 Mar; 26(3):481-9.
View in: PubMed

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117(12):3421-9.
View in: PubMed

NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 2011 Feb; 25(2):281-9.
View in: PubMed

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin. 2010 Dec; 26(12):2861-9.
View in: PubMed

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer. 2010 Oct; 1(10):1021-32.
View in: PubMed

Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010 Dec; 24(12):2100-9.
View in: PubMed

Discovery and characterization of novel mutant FLT3 kinase inhibitors. . 2010 Sep; 9(9):2468-77.
View in: PubMed

Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer. 2010 Aug; 1(8):822-35.
View in: PubMed

Drug resistance in mutant FLT3-positive AML. Oncogene. 2010 Sep 16; 29(37):5120-34.
View in: PubMed

Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
View in: PubMed

Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia. 2010 Jul; 24(7):1375-8.
View in: PubMed

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010 May 27; 115(21):4206-16.
View in: PubMed

The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem. 2010 May 07; 285(19):14356-65.
View in: PubMed

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
View in: PubMed

Wnt/ß-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3ß Dependent Manner. Genes Cancer. 2010 Feb; 1(2):164-76.
View in: PubMed

A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. Mol Cell Proteomics. 2010 May; 9(5):780-90.
View in: PubMed

Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer. 2010 Jan 19; 102(2):351-60.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

JAK2 gets histone H3 rolling. Cancer Cell. 2009 Nov 06; 16(5):365-6.
View in: PubMed

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009 Aug 27; 114(9):1813-9.
View in: PubMed

Treatment patterns of chronic myelogenous leukemia patients with suboptimal responses to imatinib. J Clin Oncol. 2009 May 20; 27(15_suppl):7090.
View in: PubMed

Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelegenous leukemia. J Clin Oncol. 2009 May 20; 27(15_suppl):7092.
View in: PubMed

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat. 2009 Jun; 12(3):81-9.
View in: PubMed

Following the cytokine signaling pathway to leukemogenesis: a chronology. J Clin Invest. 2008 Nov; 118(11):3564-73.
View in: PubMed

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood. 2008 Dec 15; 112(13):5161-70.
View in: PubMed

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. . 2008 May; 7(5):1121-9.
View in: PubMed

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 01; 111(9):4788-96.
View in: PubMed

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008 Apr 01; 111(7):3751-9.
View in: PubMed

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood. 2008 Apr 01; 111(7):3723-34.
View in: PubMed

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007 Dec; 12(6):501-13.
View in: PubMed

The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Blood. 2007 Nov 15; 110(10):3618-23.
View in: PubMed

Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. . 2007 Jul; 6(7):1951-61.
View in: PubMed

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007 May; 7(5):345-56.
View in: PubMed

The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem. 2007 Apr 20; 282(16):11969-81.
View in: PubMed

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007 Jun 01; 109(11):5011-5.
View in: PubMed

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007 Mar; 117(3):730-8.
View in: PubMed

NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia. 2007 Mar; 21(3):462-71.
View in: PubMed

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 01; 109(5):2112-20.
View in: PubMed

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology. 2006 Dec; 131(6):1734-42.
View in: PubMed

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15; 354(24):2542-51.
View in: PubMed

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19; 94(12):1765-9.
View in: PubMed

Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem. 2006 Jun 30; 281(26):18177-83.
View in: PubMed

The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev. 2006 Mar 15; 20(6):675-88.
View in: PubMed

A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood. 2006 Feb 01; 107(3):1237-8.
View in: PubMed

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec 15; 24(56):8259-67.
View in: PubMed

FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene. 2005 Nov 24; 24(53):7882-92.
View in: PubMed

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 2005 Oct 01; 65(19):8968-74.
View in: PubMed

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005 Nov 15; 106(10):3377-9.
View in: PubMed

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005 Nov 01; 106(9):3206-13.
View in: PubMed

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005 Jul 01; 11(13):4941-7.
View in: PubMed

Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J. 2005 Jul 06; 24(13):2391-402.
View in: PubMed

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
View in: PubMed

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 2005 Jul 15; 106(2):721-4.
View in: PubMed

Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005 Jun; 19(8):960-2.
View in: PubMed

Interaction maps for kinase inhibitors. Nat Biotechnol. 2005 Mar; 23(3):308-9.
View in: PubMed

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb; 7(2):129-41.
View in: PubMed

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia. 2004 Dec; 18(12):1951-63.
View in: PubMed

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23.
View in: PubMed

Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol. 2004 Oct; 14(5):348-56.
View in: PubMed

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14479-84.
View in: PubMed

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004 Sep 15; 64(18):6385-9.
View in: PubMed

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005 Jan 01; 105(1):350-7.
View in: PubMed

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005 Jan 01; 105(1):22-30.
View in: PubMed

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 01; 105(1):54-60.
View in: PubMed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
View in: PubMed

Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest. 2004 Jun; 113(12):1784-91.
View in: PubMed

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene. 2004 Apr 22; 23(19):3338-49.
View in: PubMed

Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. Gene. 2004 Mar 17; 328:153-65.
View in: PubMed

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem. 2004 Mar; 4(3):285-99.
View in: PubMed

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):3130-5.
View in: PubMed

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004 Jun 15; 103(12):4622-9.
View in: PubMed

The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors. Int J Hematol. 2004 Feb; 79(2):138-46.
View in: PubMed

FLT3 tyrosine kinase as a target in acute leukemias. Hematol J. 2004; 5 Suppl 3:S188-90.
View in: PubMed

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. Ann Hematol. 2004; 83 Suppl 1:S89-90.
View in: PubMed

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2004 Apr 01; 103(7):2802-5.
View in: PubMed

Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk Lymphoma. 2003 Nov; 44(11):1987-96.
View in: PubMed

Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat. 2003 Oct; 6(5):231-8.
View in: PubMed

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
View in: PubMed

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
View in: PubMed

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69.
View in: PubMed

Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003 Apr; 40(2 Suppl 2):4-10.
View in: PubMed

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14.
View in: PubMed

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83.
View in: PubMed

t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet. 2003 Feb; 33(2):208-13.
View in: PubMed

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol. 2003; 532:121-40.
View in: PubMed

Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003; 82-101.
View in: PubMed

Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol. 2003 Jan; 23(2):655-64.
View in: PubMed

Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol. 2002 Nov; 22(21):7688-700.
View in: PubMed

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
View in: PubMed

The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002 Sep 01; 100(5):1532-42.
View in: PubMed

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002 Nov 15; 100(10):3767-75.
View in: PubMed

Role of FLT3 in leukemia. Curr Opin Hematol. 2002 Jul; 9(4):274-81.
View in: PubMed

Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002 Jun; 1(5):479-92.
View in: PubMed

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002 Jun; 1(5):433-43.
View in: PubMed

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002 May 13; 21(21):3314-33.
View in: PubMed

A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem. 2002 Jun 07; 277(23):20887-94.
View in: PubMed

Brain armadillo protein delta-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. J Neurosci Res. 2002 Mar 01; 67(5):618-24.
View in: PubMed

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33.
View in: PubMed

Resistance to targeted therapy in leukaemia. Lancet. 2002 Feb 09; 359(9305):458-9.
View in: PubMed

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15; 99(2):664-71.
View in: PubMed

Leukemia stem cells and constitutive activation of NF-kappaB. Blood. 2001 Oct 15; 98(8):2291.
View in: PubMed

The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem. 2001 Nov 30; 276(48):44889-97.
View in: PubMed

Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia. 2001 Sep; 15(9):1424-32.
View in: PubMed

Notch receptors and hematopoiesis. Exp Hematol. 2001 Sep; 29(9):1041-52.
View in: PubMed

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
View in: PubMed

Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development. Cancer Chemother Pharmacol. 2001 Aug; 48 Suppl 1:S11-6.
View in: PubMed

Point mutations in the FLT3 gene in AML. Blood. 2001 Apr 15; 97(8):2193A-2193.
View in: PubMed

ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001 Apr 15; 97(8):2440-8.
View in: PubMed

Investigator profile: James D. Griffin M.D. interviewed by Vicki P. Glaser. J Hematother Stem Cell Res. 2001 Apr; 10(2):209-14.
View in: PubMed

Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol. 2001 Apr; 73(3):278-91.
View in: PubMed

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Updat. 2001 Feb; 4(1):22-8.
View in: PubMed

BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000 Dec 15; 275(50):39223-30.
View in: PubMed

MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet. 2000 Dec; 26(4):484-9.
View in: PubMed

Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci. 2000 Dec; 113 Pt 23:4313-8.
View in: PubMed

The ABL kinase inhibitor STI571 does not affect survival of hematopoietic cells after ionizing radiation. Blood. 2000 Nov 01; 96(9):3294-5.
View in: PubMed

SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8.
View in: PubMed

Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000 Sep 15; 96(6):2269-76.
View in: PubMed

The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8.
View in: PubMed

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000 Jul 20; 19(31):3521-8.
View in: PubMed

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000 Jun 01; 95(11):3498-505.
View in: PubMed

STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000 Mar 15; 95(6):2118-25.
View in: PubMed

The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. J Biol Chem. 2000 Jan 14; 275(2):1405-13.
View in: PubMed

Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature. Leukemia. 2000 Jan; 14(1):169-82.
View in: PubMed

The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration. J Biol Chem. 1999 Dec 31; 274(53):37525-32.
View in: PubMed

The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999 Dec 17; 274(51):36684-92.
View in: PubMed

The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46.
View in: PubMed

Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. J Biol Chem. 1999 Nov 19; 274(47):33522-30.
View in: PubMed

BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol. 1999 Nov; 19(11):7473-80.
View in: PubMed

Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice. Protein Eng. 1999 Sep; 12(9):779-85.
View in: PubMed

Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. 1999 Jun 03; 18(22):3343-53.
View in: PubMed

Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 01; 93(9):2928-35.
View in: PubMed

Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann N Y Acad Sci. 1999 Apr 30; 872:305-12; discussion 312-3.
View in: PubMed

Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene. 1999 Jan 07; 18(1):67-77.
View in: PubMed

Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation. Oncogene. 1998 Dec 10; 17(23):2961-71.
View in: PubMed

The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. Blood. 1998 Nov 15; 92(10):3848-56.
View in: PubMed

Microinjection of a cyclooxygenase inhibitor into the anteroventral preoptic region attenuates LPS fever. Am J Physiol. 1998 03; 274(3):R783-9.
View in: PubMed

The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem. 1997 Dec 26; 272(52):33373-6.
View in: PubMed

Signaling functions of the tyrosine residues in the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. Blood. 1997 Dec 15; 90(12):4759-66.
View in: PubMed

Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood. 1997 Dec 15; 90(12):4687-98.
View in: PubMed

Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol. 1997 Dec; 25(13):1367-77.
View in: PubMed

The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene. 1997 Nov 06; 15(19):2379-84.
View in: PubMed

A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo. J Clin Invest. 1997 Oct 01; 100(7):1708-15.
View in: PubMed

BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 1997 Jul 01; 100(1):46-57.
View in: PubMed

Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells. J Biol Chem. 1997 Jun 27; 272(26):16421-30.
View in: PubMed

Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997 May 30; 272(22):14320-6.
View in: PubMed

Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997 Apr 11; 272(15):10248-53.
View in: PubMed

Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997 Apr; 171(1):28-33.
View in: PubMed

Determinants of hypothalamic neuronal thermosensitivity. Ann N Y Acad Sci. 1997 Mar 15; 813:133-8.
View in: PubMed

The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins. Leukemia. 1997 Mar; 11(3):376-85.
View in: PubMed

Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem. 1997 Feb 14; 272(7):4230-6.
View in: PubMed

Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol. 1997 Jan; 25(1):45-50.
View in: PubMed

The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem. 1996 Dec 06; 271(49):31222-6.
View in: PubMed

The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11681-6.
View in: PubMed

p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996 Oct 11; 271(41):25198-203.
View in: PubMed

Ventromedial preoptic prostaglandin E2 activates fever-producing autonomic pathways. J Neurosci. 1996 Oct 01; 16(19):6246-54.
View in: PubMed

p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996 Sep 19; 13(6):1147-52.
View in: PubMed

Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest. 1996 Jul 15; 98(2):521-8.
View in: PubMed

Tyrosine phosphorylation of Shc is not required for proliferation or viability signaling by granulocyte-macrophage colony-stimulating factor in hematopoietic cell lines. J Immunol. 1996 Jul 15; 157(2):534-40.
View in: PubMed

Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 1996 Jul; 94(1):5-16.
View in: PubMed

Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med. 1996 Mar 01; 183(3):811-20.
View in: PubMed

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene. 1996 Feb 15; 12(4):839-46.
View in: PubMed

B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996 Feb 01; 156(3):1126-31.
View in: PubMed

p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996 Feb; 24(2):310-3.
View in: PubMed

Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene. 1995 Sep 21; 11(6):1149-55.
View in: PubMed

Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci U S A. 1995 Sep 12; 92(19):8665-9.
View in: PubMed

The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
View in: PubMed

Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995 May 01; 85(9):2507-15.
View in: PubMed

Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995 May; 49(1):29-38.
View in: PubMed

The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem. 1995 Mar 10; 270(10):4979-82.
View in: PubMed

Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells. Oncogene. 1995 Feb 16; 10(4):751-5.
View in: PubMed

The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line. Leukemia. 1995 Feb; 9(2):295-301.
View in: PubMed

Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J. 1995 Jan 16; 14(2):257-65.
View in: PubMed

A low affinity chimeric human alpha/beta-granulocyte-macrophage colony-stimulating factor receptor induces ligand-dependent proliferation in a murine cell line. J Biol Chem. 1994 Dec 02; 269(48):30173-80.
View in: PubMed

CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 1994 Nov 01; 180(5):1665-73.
View in: PubMed

Inhibition of p21ras activation blocks proliferation but not differentiation of interleukin-3-dependent myeloid cells. J Biol Chem. 1994 Oct 07; 269(40):24602-7.
View in: PubMed

Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol. 1994 Oct; 22(11):1111-7.
View in: PubMed

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994 Sep 16; 269(37):22925-8.
View in: PubMed

Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression. Blood. 1994 Aug 01; 84(3):789-94.
View in: PubMed

JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 1994 Jul; 14(7):4335-41.
View in: PubMed

Signal transduction of steel factor and granulocyte-macrophage colony-stimulating factor: differential regulation of transcription factor and G1 cyclin gene expression, and of proliferation in the human factor-dependent cell line MO7. Leukemia. 1994 May; 8(5):740-8.
View in: PubMed

Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol. 1994 Apr; 45(4):283-7.
View in: PubMed

p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem. 1994 Feb 25; 269(8):5764-9.
View in: PubMed

rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils. J Biol Chem. 1994 Feb 18; 269(7):5387-90.
View in: PubMed

Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem. 1994 Feb 18; 269(7):5016-21.
View in: PubMed

Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene. 1994 Jan; 9(1):149-56.
View in: PubMed

Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A. 1993 Oct 15; 90(20):9571-5.
View in: PubMed

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
View in: PubMed

Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun; 43(2):95-102.
View in: PubMed

The human granulocyte-macrophage colony-stimulating factor receptor is capable of initiating signal transduction in NIH3T3 cells. EMBO J. 1993 Apr; 12(4):1647-56.
View in: PubMed

Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem. 1993 Feb 25; 268(6):4113-9.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor-dependent hematopoietic cell line. J Cell Physiol. 1992 Oct; 153(1):176-86.
View in: PubMed

Interferon-gamma increases the expression of the gene encoding the beta subunit of the granulocyte-macrophage colony-stimulating factor receptor. Blood. 1992 Oct 01; 80(7):1736-42.
View in: PubMed

Transforming growth factor-beta inhibits phosphorylation of the retinoblastoma susceptibility gene product in human monocytic leukemia cell line JOSK-I. J Biol Chem. 1992 Aug 25; 267(24):17121-7.
View in: PubMed

Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood. 1992 Aug 15; 80(4):1083-9.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood. 1992 Jun 01; 79(11):2880-7.
View in: PubMed

Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992 May 01; 79(9):2229-36.
View in: PubMed

Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 1992 May 01; 79(9):2215-20.
View in: PubMed

Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Hematol. 1992 May; 20(4):442-8.
View in: PubMed

Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose. J Cell Physiol. 1992 Mar; 150(3):484-92.
View in: PubMed

The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A. 1992 Mar 01; 89(5):1795-8.
View in: PubMed

Surface immunoglobulin-mediated signal transduction involves rapid phosphorylation and activation of the protooncogene product Raf-1 in human B-cells. Cancer Res. 1992 Feb 01; 52(3):566-70.
View in: PubMed

Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood. 1992 Feb 01; 79(3):657-65.
View in: PubMed

Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood. 1991 Dec 01; 78(11):2834-40.
View in: PubMed

Granulocyte colony-stimulating factor and its receptor. Blood. 1991 Dec 01; 78(11):2791-808.
View in: PubMed

Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991 Dec 01; 78(11):2962-8.
View in: PubMed

Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells. Blood. 1991 Oct 15; 78(8):1928-35.
View in: PubMed

Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol. 1991 Oct 15; 147(8):2565-73.
View in: PubMed

CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood. 1991 Oct 01; 78(7):1834-41.
View in: PubMed

Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene. 1991 Aug; 6(8):1343-6.
View in: PubMed

Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 1991 Jun 01; 77(11):2404-12.
View in: PubMed

Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15; 77(10):2242-50.
View in: PubMed

Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia. 1991 Apr; 5(4):300-8.
View in: PubMed

Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies. Blood. 1991 Mar 01; 77(5):1033-43.
View in: PubMed

Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991 Mar; 5(3):230-8.
View in: PubMed

Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature. 1991 Feb 21; 349(6311):691-4.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line. Blood. 1991 Jan 15; 77(2):243-8.
View in: PubMed

Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. J Biol Chem. 1991 Jan 05; 266(1):490-5.
View in: PubMed

cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science. 1990 Nov 09; 250(4982):805-8.
View in: PubMed

Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest. 1990 Oct; 86(4):1261-9.
View in: PubMed

The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood. 1990 Aug 15; 76(4):716-20.
View in: PubMed

Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 1990 Aug 15; 76(4):706-15.
View in: PubMed

Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells. J Biol Chem. 1990 Jul 25; 265(21):12656-63.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J Immunol. 1990 Jul 15; 145(2):576-84.
View in: PubMed

Demonstration of interleukin-1 beta transcripts in acute myeloblastic leukemic cells by in situ hybridization. Leukemia. 1990 Jul; 4(7):466-70.
View in: PubMed

Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail? J Clin Oncol. 1990 May; 8(5):761-4.
View in: PubMed

Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci U S A. 1990 Apr; 87(7):2770-4.
View in: PubMed

The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990 Jan; 8 Suppl 1:35-44; discussion 44-5.
View in: PubMed

Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):93-7.
View in: PubMed

Cellular interaction regulating the production of colony-stimulating factors. Prog Clin Biol Res. 1990; 338:129-41.
View in: PubMed

Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol. 1989 Dec 01; 143(11):3543-7.
View in: PubMed

Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989 Nov 01; 56(3):425-30.
View in: PubMed

Colony-stimulating factor gene expression in human acute myeloblastic leukemia cells is posttranscriptionally regulated. Leukemia. 1989 Sep; 3(9):620-5.
View in: PubMed

Hemopoietins and leukemia. Hematol Oncol Clin North Am. 1989 Sep; 3(3):535-53.
View in: PubMed

Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989 Aug 15; 74(3):940-6.
View in: PubMed

Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages. Leukemia. 1989 Jun; 3(6):405-12.
View in: PubMed

Expression of the three myeloid cell-associated immunoglobulin G Fc receptors defined by murine monoclonal antibodies on normal bone marrow and acute leukemia cells. Blood. 1989 May 15; 73(7):1951-6.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia. 1989 May; 3(5):328-34.
View in: PubMed

Effects of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSFrh) on transmembrane electrical potentials in granulocytes: relationship between enhancement of ligand-mediated depolarization and augmentation of superoxide anion (O2-) production. J Cell Physiol. 1989 May; 139(2):361-9.
View in: PubMed

An elevation in the concentration of free cytosolic calcium is sufficient to activate the oxidative burst of granulocytes primed with recombinant human granulocyte-macrophage colony-stimulating factor. J Biol Chem. 1989 Apr 15; 264(11):6302-9.
View in: PubMed

Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J Biol Chem. 1989 Apr 05; 264(10):5700-3.
View in: PubMed

Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989 Apr; 30(4):221-7.
View in: PubMed

Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte-macrophage colony-stimulating factor. Br J Haematol. 1989 Apr; 71(4):475-9.
View in: PubMed

Hemopoietins in oncology: factoring out myelosuppression. J Clin Oncol. 1989 Feb; 7(2):151-5.
View in: PubMed

Functional consequences of monocyte IL-2 receptor expression. Induction of IL-1 beta secretion by IFN gamma and IL-2. J Immunol. 1989 Jan 01; 142(1):139-43.
View in: PubMed

Regulation of colony-stimulating factor production by normal and leukemic human cells. Immunol Res. 1989; 8(3):202-14.
View in: PubMed

Infection of hematopoietic and stromal cells in human continuous bone marrow cultures by a retroviral vector containing the neomycin resistance gene. Acta Haematol. 1989; 82(3):136-43.
View in: PubMed

Cloning and expression of a gamma-interferon-inducible gene in monocytes: a new member of a cytokine gene family. Int Immunol. 1989; 1(4):388-97.
View in: PubMed

Monocyte interleukin-1 secretion is regulated by the sequential action of gamma-interferon and interleukin-2 involving monocyte surface expression of interleukin-2 receptors. Haematol Blood Transfus. 1989; 32:299-315.
View in: PubMed

Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation. Blood. 1989 Jan; 73(1):131-6.
View in: PubMed

Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol. 1988 Dec; 11(6):623-6.
View in: PubMed

Effects of recombinant human granulocyte-macrophage colony-stimulating factor on intracellular pH in mature granulocytes. Blood. 1988 Nov; 72(5):1665-73.
View in: PubMed

Monocytes enhance gamma-interferon-induced inhibition of myeloid progenitor cell growth through secretion of tumor necrosis factor. Exp Hematol. 1988 Nov; 16(10):865-70.
View in: PubMed

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 08; 319(10):593-8.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. Blood. 1988 Aug; 72(2):691-7.
View in: PubMed

Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol. 1988 Jul 15; 141(2):575-9.
View in: PubMed

Regulation of the production and function of granulocytes and monocytes. Semin Hematol. 1988 Jul; 25(3):173-88.
View in: PubMed

Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood. 1988 Jun; 71(6):1529-32.
View in: PubMed

In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells. Exp Hematol. 1988 Jun; 16(5):378-82.
View in: PubMed

Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988 May 28; 1(8596):1194-8.
View in: PubMed

Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med. 1988 May 05; 318(18):1153-8.
View in: PubMed

Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest. 1988 Apr; 81(4):1030-5.
View in: PubMed

Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TU 67). Blut. 1988 Apr; 56(4):179-83.
View in: PubMed

Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood. 1988 Mar; 71(3):672-6.
View in: PubMed

Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest. 1988 Feb; 81(2):624-9.
View in: PubMed

Clinical applications of colony-stimulating factors. Oncology (Williston Park). 1988 Jan; 2(1):15-23.
View in: PubMed

The biology of acute myeloblastic leukemia. Semin Oncol. 1987 Dec; 14(4):365-71.
View in: PubMed

Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. J Immunol. 1987 Nov 15; 139(10):3422-30.
View in: PubMed

Growth factors required for proliferation of clonogenic cells in acute myeloblastic leukemia (AML). Haematologica. 1987 Nov-Dec; 72(6 Suppl):85-8.
View in: PubMed

Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987 Oct; 70(4):1218-21.
View in: PubMed

Acquisition of formyl peptide receptors during normal human myeloid differentiation. Blood. 1987 Oct; 70(4):1222-4.
View in: PubMed

Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia. 1987 Aug; 1(8):584-9.
View in: PubMed

Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest. 1987 Jun; 79(6):1720-8.
View in: PubMed

The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood. 1987 Jun; 69(6):1771-6.
View in: PubMed

Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside. Semin Oncol. 1987 Jun; 14(2 Suppl 1):149-58.
View in: PubMed

Expression of the M-CSF (CSF-1) gene by human monocytes. Blood. 1987 May; 69(5):1409-13.
View in: PubMed

Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. Cell Immunol. 1987 May; 106(2):355-65.
View in: PubMed

Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987 Apr 30; 316(18):1111-7.
View in: PubMed

Southern blot analysis of BII cell line--a putative variant of HL-60. Leukemia. 1987 Feb; 1(2):142-5.
View in: PubMed

The effects of phorbol myristate acetate and chemotactic peptide on transmembrane potentials and cytosolic free calcium in mature granulocytes evolve sequentially as the cells differentiate. J Biol Chem. 1987 Jan 25; 262(3):1274-81.
View in: PubMed

Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest. 1987 Jan; 79(1):100-6.
View in: PubMed

Interferon-gamma induces expression of the interleukin 2 receptor gene in human monocytes. Eur J Immunol. 1987 Jan; 17(1):153-6.
View in: PubMed

Leukemic colony-forming cells in acute myeloblastic leukemia: maturation hierarchy and growth conditions. Haematol Blood Transfus. 1987; 31:185-90.
View in: PubMed

The use of monoclonal antibodies in the characterization of myeloid leukemias. Hematol Pathol. 1987; 1(2):81-91.
View in: PubMed

In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. Blood. 1987 Jan; 69(1):246-54.
View in: PubMed

Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1232-41.
View in: PubMed

Clonogenic cells in acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1185-95.
View in: PubMed

Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J Immunol. 1986 Nov 15; 137(10):3259-63.
View in: PubMed

Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood. 1986 Nov; 68(5):1178-81.
View in: PubMed

The role of colony stimulating factors in leukaemogenesis. Clin Haematol. 1986 Nov; 15(4):995-1002.
View in: PubMed

Biology of acute myeloid leukaemia. Clin Haematol. 1986 Aug; 15(3):641-67.
View in: PubMed

Management of chronic myelogenous leukemia. Semin Hematol. 1986 Jul; 23(3 Suppl 1):20-6.
View in: PubMed

Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood. 1986 May; 67(5):1448-53.
View in: PubMed

T cell-monocyte interactions in the production of humoral factors regulating human granulopoiesis in vitro. J Immunol. 1986 Apr 15; 136(8):2856-61.
View in: PubMed

Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood. 1986 Apr; 67(4):898-902.
View in: PubMed

Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis. J Immunol. 1986 Mar 01; 136(5):1629-34.
View in: PubMed

Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implications for prostaglandin E resistance in chronic myeloid leukemia. J Clin Invest. 1986 Jan; 77(1):13-20.
View in: PubMed

A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-target cell interactions. J Exp Med. 1985 Dec 01; 162(6):2035-52.
View in: PubMed

TPA induces differentiation of purified human myeloblasts in the absence of proliferation. Exp Hematol. 1985 Nov; 13(10):1025-32.
View in: PubMed

Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells. Scand J Haematol. 1985 Oct; 35(4):408-17.
View in: PubMed

Differential expression of HLA-DR antigens in subsets of human CFU-GM. Blood. 1985 Oct; 66(4):788-95.
View in: PubMed

Clonogenic cells in acute myeloblastic leukaemia. Scand J Haematol. 1985 Sep; 35(3):251-6.
View in: PubMed

Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. Semin Oncol. 1985 Sep; 12(3):281-8.
View in: PubMed

Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med. 1985 Sep 01; 162(3):1111-6.
View in: PubMed

Detection of nonrandom clustering of colonies in agar culture. Exp Hematol. 1985 Aug; 13(7):696-700.
View in: PubMed

Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique. Exp Hematol. 1985 Jul; 13(6):560-5.
View in: PubMed

Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol. 1985 Jul; 3(7):982-91.
View in: PubMed

Amsacrine in refractory acute leukemia. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):787-9.
View in: PubMed

Mb1, a plasma membrane antigen selectively expressed by U-937 cells. Blood. 1985 Jul; 66(1):135-42.
View in: PubMed

Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9. Hematol Oncol. 1985 Jul-Sep; 3(3):179-86.
View in: PubMed

Cellular and clinical pharmacology of low-dose ara-C. Semin Oncol. 1985 Jun; 12(2 Suppl 3):200-7.
View in: PubMed

Use of SM-1 monoclonal antibody and human complement in selective killing of small cell carcinoma of the lung. J Clin Invest. 1985 May; 75(5):1690-5.
View in: PubMed

Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1985 Mar; 75(3):1008-14.
View in: PubMed

Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung. Cancer Res. 1985 Mar; 45(3):1026-32.
View in: PubMed

Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest. 1985 Mar; 75(3):932-43.
View in: PubMed

Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest. 1985 Feb; 75(2):746-53.
View in: PubMed

Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells. Blood. 1985 Feb; 65(2):414-22.
View in: PubMed

Acute undifferentiated leukemia: induction of partial differentiation by phorbol ester. Leuk Res. 1985; 9(1):11-7.
View in: PubMed

Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984 Sep; 64(3):662-6.
View in: PubMed

A pericentric inversion of chromosome 16 is associated with dysplastic marrow eosinophils in acute myelomonocytic leukemia. Blood. 1984 Apr; 63(4):800-2.
View in: PubMed

Induction of proliferation of purified human myeloid progenitor cells: a rapid assay for granulocyte colony-stimulating factors. Blood. 1984 Apr; 63(4):904-11.
View in: PubMed

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984; 8(4):521-34.
View in: PubMed

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med. 1983 Dec 29; 309(26):1599-602.
View in: PubMed

Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. Blood. 1983 Dec; 62(6):1300-3.
View in: PubMed

Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type). Cancer Genet Cytogenet. 1983 Oct; 10(2):167-75.
View in: PubMed

Microgranular acute promyelocytic leukemia diagnosed by flow cytometry. N Engl J Med. 1983 Aug 18; 309(7):435.
View in: PubMed

Isolation and characterization of human B lymphocyte enriched populations. I. Purification of B cells by immune rosette depletion. J Immunol Methods. 1983 Jul 29; 61(3):283-92.
View in: PubMed

Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol. 1983 Jul; 131(1):232-7.
View in: PubMed

Idiopathic thrombocytopenia in association with extragonadal germ cell cancer. Ann Intern Med. 1983 Jun; 98(6):926-7.
View in: PubMed

Characterization of an antigen expressed by human natural killer cells. J Immunol. 1983 Jun; 130(6):2947-51.
View in: PubMed

Expression of MY7 antigen on myeloid precursor cells. Int J Cell Cloning. 1983 Apr; 1(1):33-48.
View in: PubMed

T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood. 1983 Apr; 61(4):640-4.
View in: PubMed

Conservation of myeloid surface antigens on primate granulocytes. Blood. 1983 Feb; 61(2):408-10.
View in: PubMed

Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med. 1983 Jan 01; 157(1):114-29.
View in: PubMed

Electrocardiogram abnormalities induced by amsacrine. Cancer Chemother Pharmacol. 1983; 10(2):133-4.
View in: PubMed

Effect of phorbol ester on differentiation of human myeloid colony forming cells (CFU-C). Leuk Res. 1983; 7(1):43-9.
View in: PubMed

Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
View in: PubMed

Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients. Blood. 1982 Jul; 60(1):30-7.
View in: PubMed

Relationship of oligomerization to enzymatic and DNA-binding properties of the SV40 large T antigen. Cell. 1982 Jan; 28(1):125-34.
View in: PubMed

Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest. 1981 Oct; 68(4):932-41.
View in: PubMed

Eye toxicity of cancer chemotherapy: a review of the literature. Cancer. 1981 Oct 01; 48(7):1539-49.
View in: PubMed

Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol. 1981; 12:187-225.
View in: PubMed

Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res. 1981; 5(6):491-5.
View in: PubMed

A blast subclone of the HL-60 human promyelocytic cell line. Leuk Res. 1981; 5(4-5):429-30.
View in: PubMed

Identification and initial characterization of a new low-molecular-weight virus-encoded T antigen in a line of simian virus 40-transformed cells. J Virol. 1980 Nov; 36(2):488-98.
View in: PubMed

Enzymatic activities associated with the SV40 large T antigen. Cold Spring Harb Symp Quant Biol. 1980; 44 Pt 1,:113-22.
View in: PubMed

Protein kinase activity associated with simian virus 40 T antigen. Proc Natl Acad Sci U S A. 1979 Jun; 76(6):2610-4.
View in: PubMed

Phenotypic complementation of the SV40 tsA mutant defect in viral DNA synthesis following microinjection of SV40 T antigen. Cell. 1978 Aug; 14(4):983-94.
View in: PubMed

Measurements of the molecular size of the simian virus 40 large T antigen. J Virol. 1978 Jul; 27(1):218-26.
View in: PubMed

Lymphocytic thymoma associated with T-cell lymphocytosis. Am J Med. 1978 Jun; 64(6):1075-9.
View in: PubMed

Development of a histiocytic medullary reticulosis-like syndrome during the course of acute lymphocytic leukemia. Am J Med. 1978 May; 64(5):851-8.
View in: PubMed

Epsilon-aminocaproic acid (EACA). Semin Thromb Hemost. 1978; 5(1):27-40.
View in: PubMed

Ouabain antagonism of smooth muscle contraction. J Pharmacol Exp Ther. 1972 Sep; 182(3):378-87.
View in: PubMed

Methylxanthine-induced escalation: a propagated wave phenomenon observed in skeletal muscle developing in culture. Proc Natl Acad Sci U S A. 1972 Mar; 69(3):613-6.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana D1608
Boston, MA 02215
Get Directions

Top